{"id":5034,"date":"2020-07-27T16:44:15","date_gmt":"2020-07-27T14:44:15","guid":{"rendered":"https:\/\/www.bm-t.de\/v4\/2020\/10\/07\/neurocare-group-receives-2nd-investment-from-bmt-to-fund-further-expansion\/"},"modified":"2020-11-05T12:08:40","modified_gmt":"2020-11-05T11:08:40","slug":"neurocare-group-receives-2nd-investment-from-bmt-to-fund-further-expansion","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2020-en\/neurocare-group-receives-2nd-investment-from-bmt-to-fund-further-expansion\/","title":{"rendered":"neuroCare Group receives 2<sup class=\"ordinal\">nd<\/sup> investment from bm|t to fund further expansion"},"content":{"rendered":"<div>neu\u00adro\u00adCare is pleased to announce the clos\u00ading of a seven-fig\u00adure invest\u00adment with Kyowa Phar\u00adma\u00adceu\u00adti\u00adcals and bm|t \u2013 the company\u00b4s lead investor. This invest\u00adment will not only finance the company\u00b4s fur\u00adther expan\u00adsion, includ\u00ading its Japan mar\u00adket entry, but also will safe\u00adguard neuroCare\u2019s growth and planned IPO beyond the cur\u00adrent COVID19 cri\u00adsis. neuroCare\u00b4s pur\u00adpose is to per\u00adson\u00adal\u00adize men\u00adtal health\u00adcare and per\u00adfor\u00admance. Through neuroCare\u00b4s plat\u00adform, clin\u00adi\u00adcians are empow\u00adered to pro\u00advide per\u00adson\u00adal\u00adized and med\u00adica\u00adtion-free ther\u00adapy that addresses the under\u00adly\u00ading root causes of men\u00adtal ill\u00adness by improv\u00ading patients\u00b4 abil\u00adity to self-reg\u00adu\u00adlate. neuroCare\u2019s approach gen\u00ader\u00adates best-in-class clin\u00adi\u00adcal out\u00adcomes that are sus\u00adtain\u00adable over the long term and with\u00adout neg\u00ada\u00adtive side effects. neu\u00adro\u00adCare is ver\u00adti\u00adcally inte\u00adgrated, oper\u00adat\u00ading its own neu\u00adro\u00adClin\u00adics as well as pro\u00advid\u00ading its tech\u00adnolo\u00adgies, Stan\u00addard Oper\u00adat\u00ading Pro\u00adce\u00addures and edu\u00adca\u00adtion to its inhouse and third-party clin\u00adics through its neu\u00adroSo\u00adlu\u00adtions divi\u00adsion. Within the neu\u00adroSo\u00adlu\u00adtions divi\u00adsion, neu\u00adro\u00adCad\u00ademy pro\u00advides Train\u00ading and Sci\u00adence &amp; Super\u00advi\u00adsion and neu\u00adro\u00adConn pro\u00advides neu\u00adro\u00admod\u00adu\u00adla\u00adtion tech\u00adnol\u00adogy. These key build\u00ading blocks enable neu\u00adro\u00adCare to sup\u00adport a grow\u00ading global net\u00adwork of clin\u00adi\u00adcians. bm|t is the pre\u00admier investor in the state of Th\u00fcrin\u00adgen and has a wealth of life sci\u00adence invest\u00ading expe\u00adri\u00adence, includ\u00ading invest\u00adments in mul\u00adti\u00adple pub\u00adlicly traded health\u00adcare com\u00adpa\u00adnies. Kevin Reeder, bm|t\u00b4s CEO, said of the company\u00b4s invest\u00adment in neu\u00adro\u00adCare, \u201cWe are pleased to have re-invested in neu\u00adro\u00adCare. We believe strongly in the company\u00b4s lead\u00ader\u00adship and pur\u00adpose and are eager to see the com\u00adpany con\u00adtinue on its path towards global lead\u00ader\u00adship, espe\u00adcially now, con\u00adsid\u00ader\u00ading the expected men\u00adtal health strains caused by the cur\u00adrent COVID19 cri\u00adsis.\u201d Tom Mechter\u00adsheimer, neuroCare\u00b4s founder and Exec\u00adu\u00adtive Chair, con\u00adcluded by stat\u00ading that \u201cneu\u00adro\u00adCare is dri\u00adving the future of men\u00adtal health and cog\u00adni\u00adtive per\u00adfor\u00admance with per\u00adson\u00adal\u00adized, objec\u00adtive and mea\u00adsur\u00adable out\u00adcomes for every patient. We are very grate\u00adful for the con\u00adtin\u00adued trust of bm|t who shares our con\u00advic\u00adtion that men\u00adtal health, espe\u00adcially due to the effects of COVID-19, will be a major cri\u00adsis to be addressed for a long time to come. Our pro\u00adduc\u00adtive and cost-effec\u00adtive approach will help patients, clin\u00adi\u00adcians and pay\u00adors to deal with that huge challenge.\u201d<\/div>\n<h3><strong>About <a href=\"https:\/\/www.neurocaregroup.com\/start.html\" target=\"_blank\" rel=\"noopener noreferrer\">neuroCare Group<\/a><\/strong><\/h3>\n<p>The neu\u00adro\u00adCare Group (nCG) is a fast-grow\u00ading, ver\u00adti\u00adcally inte\u00adgrated com\u00adpany pro\u00advid\u00ading a holis\u00adtic and per\u00adson\u00adal\u00adized approach for improv\u00ading men\u00adtal health and per\u00adfor\u00admance. By inte\u00adgrat\u00ading neu\u00adro\u00admod\u00adu\u00adla\u00adtion tech\u00adnol\u00adogy with best processes and work\u00ading in syn\u00adergy with the clin\u00adi\u00adcians, neu\u00adro\u00adCare achieves best-in-class clin\u00adi\u00adcal out\u00adcome for patients. nCG employs more than 100 peo\u00adple serv\u00ading around 1500 patients per annum across 16 clin\u00adics cur\u00adrently in Aus\u00adtralia, the Nether\u00adlands and the USA. nCG\u2019s back\u00adbone in tech\u00adnol\u00adogy is based in Th\u00fcrin\u00adgen, Germany.<\/p>\n<h3>&nbsp;<\/h3>\n<h3><strong>About <a href=\"http:\/\/www.bm-t.com\" target=\"_blank\" rel=\"noopener noreferrer\">bm|t<\/a><\/strong><\/h3>\n<div>Erfurt-based, beteili\u00adgungs\u00adman\u00adage\u00adment Th\u00fcrin\u00adgen (bm|t) \u2013 a sub\u00adsidiary of the Th\u00fcrin\u00adgen Devel\u00adop\u00adment Bank, is the first address for invest\u00adments in Th\u00fcrin\u00adgen, Ger\u00admany. bm\u2011t cur\u00adrently man\u00adages eight invest\u00adment funds with a total vol\u00adume of 400M EUR. bm\u2011t invests in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies with strong growth poten\u00adtial across all sec\u00adtors and all phases of the cor\u00adpo\u00adrate lifecycle.<\/div>\n<div>&nbsp;<\/div>\n<h3><strong>About <a href=\"http:\/\/www.kyowayakuhin.com\" target=\"_blank\" rel=\"noopener noreferrer\">Kyowa Pharmaceutical<\/a><\/strong><\/h3>\n<div>Kyowa Phar\u00adma\u00adceu\u00adti\u00adcal Indus\u00adtry Co., Ltd. (\u201cKyowa\u201d)\n<div>based in Osaka, Japan is the domes\u00adtic leader in Cen\u00adtral Ner\u00advous Sys\u00adtem (CNS) ther\u00ada\u00adpeu\u00adtic area. After recently being acquired by Uni\u00adson Cap\u00adi\u00adtal, one of Japan\u2019s lead\u00ading Pri\u00advate Equity Funds, Kyowa is now real\u00adiz\u00ading its unique growth strat\u00adegy of Kyowa beyond drugs. Founded in 1954, Kyowa is proud of its long his\u00adtory being a CNS focused full-fledged generic and branded phar\u00adma\u00adceu\u00adti\u00adcal company.<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>neu\u00adro\u00adCare is pleased to announce the clos\u00ading of a seven-fig\u00adure invest\u00adment with Kyowa Phar\u00adma\u00adceu\u00adti\u00adcals and bm|t \u2013 the company\u00b4s lead investor. This invest\u00adment will not only finance the company\u00b4s fur\u00adther expan\u00adsion, includ\u00ading its Japan mar\u00adket entry, but also will safe\u00adguard neuroCare\u2019s growth and planned IPO beyond the cur\u00adrent COVID19 cri\u00adsis. neuroCare\u00b4s pur\u00adpose is to personalize&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":8438,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[149],"tags":[177,175,174],"class_list":["post-5034","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2020-en","tag-bmt-en","tag-thuringia-growth-fund","tag-wbf-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/5034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=5034"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/5034\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/8438"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=5034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=5034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=5034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}